$LSTA

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.

Lisata Therapeutics, Inc. raised $352 million in a securities offering. The company, incorporated in Delaware, is involved in the healthcare industry. The offering was filed with the SEC under Rule 506(b).

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225M in financing, diluting legacy shareholders to 2.39% ownership. The funds will support operations into 2028, covering clinical trials for severe hypertriglyceridemia and acromegaly. Success could attract partnerships or improve future financing terms, but risks include clinical trial failures and cash settlement obligations.

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and raised $225M in private financing. The deal expands Lisata's portfolio into cardioendocrine therapeutics. Proceeds will fund clinical trials for MAR001/005 and MAR002, with data expected in Q4 2027. LSTA shares rose 20.41% to $1.77. Post-transaction, former Marea equity holders will own 59.54% of Lisata.

Lisata Therapeutics (LSTA) acquired Marea Therapeutics in a stock-for-stock deal, raising $225M in private placement. Lisata shares surged 20% after the news. The acquisition focuses on advancing Marea's cardioendocrine disease treatments, with key clinical milestones expected in 2027. Investors include RA Capital, Forbion, and Third Rock Ventures.

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement Combined company to focus on developing first-in-class next - generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical produc

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Lisata Therapeutics (LSTA) said its merger with Kuva Acquisition Corp was terminated and it has sued Kuva in Delaware Chancery for breach, seeking damages including a $2 million termination fee. The board is reviewing strategic options. To cut costs, it reduced its workforce by 72%. LSTA stock closed at $1.04.

Lisata Therapeutics (NASDAQ:LSTA) said it filed suit in Delaware Chancery after Kuva Labs and Kuva Acquisition Corp terminated their March 6, 2026 merger agreement. Lisata alleges breach and seeks damages plus a $2 million termination fee. It also cut full-time roles by about 72% to preserve cash while evaluating strategic alternatives. Lead candidate is certepetide.